Loan & DebtJul 9, 2026, 06:07 AM
Kyverna Extends $15M Term A Loan Availability to Dec 2026
AI Summary
Kyverna Therapeutics, Inc. has amended its Loan and Security Agreement with Oxford Finance LLC, extending the availability of the remaining $15.0 million of Term A Loans until December 31, 2026. The company paid an upfront cash fee of $187,500 for this extension and will incur a 1.0% non-utilization fee if the funds are not fully drawn. Additionally, contingent upon drawing the full Term A amount, the availability periods for Term B and Term C loans will also be extended, with Term C being split into two $20.0 million tranches.
Key Highlights
- Kyverna amended its $150.0 million Loan and Security Agreement with Oxford Finance LLC.
- Extended the availability of the remaining $15.0 million of Term A Loans until December 31, 2026.
- Paid an upfront cash fee of $187,500 for the Term A loan extension.
- A 1.0% non-utilization fee applies if the remaining Term A Loans are not fully drawn.
- Contingent on drawing full Term A, Term B loan availability extends to September 30, 2027.
- Contingent on drawing full Term A, Term C Loans will be available in two $20.0 million tranches.
Price Impact
More from KYTX